Modernizing Opioid Treatment Access Act 2.0 of 2026
- Sponsor
- Rep. Norcross, Donald [D-NJ-1]
- Committees
- Judiciary Committee (primary)
- Last action
- Jul 20, 2026
Bottom line
The bill aims to significantly broaden patient access to methadone for opioid use disorder by enabling pharmacy dispensing under a new prescribing model, while maintaining regulatory oversight and allowing states to opt out.
What it actually does
This bill amends the Controlled Substances Act to waive current restrictions, allowing specifically qualified practitioners to prescribe methadone for opioid use disorder (OUD) to be dispensed through pharmacies. It establishes a new registration process for these prescribers, permits telemedicine for treatment, and includes a provision for states to opt out of the new prescribing model. The bill also mandates annual reporting by the DEA Administrator on the program's implementation.
Proponents argue
Proponents argue this bill is crucial for addressing the opioid crisis by removing significant barriers to methadone access, particularly for individuals in rural areas or those facing transportation challenges to traditional Opioid Treatment Programs (OTPs). They contend that allowing qualified practitioners to prescribe and pharmacies to dispense will integrate methadone treatment more seamlessly into the broader healthcare system, reducing stigma and improving patient retention. The bill's focus on qualified prescribers and informed consent ensures patient safety while expanding treatment options.
Opponents contend
Opponents might raise concerns about potential diversion risks associated with dispensing methadone through community pharmacies, arguing that the highly controlled environment of OTPs is essential for patient safety and preventing misuse. They may also worry about the adequacy of support services outside of comprehensive OTPs, suggesting that simply expanding access to the medication without robust wraparound care could lead to poorer outcomes or increased public health risks.
The bill is concise and straightforward, making it highly accessible for a reader to understand its core provisions within a short timeframe.
Section 2, amending 21 U.S.C. 823(h)(2)(A)
Expansion of Methadone Prescribing and Pharmacy Dispensing
This provision waives the existing requirements that limit methadone for opioid use disorder (OUD) to be dispensed only through Opioid Treatment Programs (OTPs). Instead, it directs the Attorney General, in consultation with the Secretary of Health and Human Services, to register qualified practitioners to prescribe methadone for OUD, allowing it to be dispensed through pharmacies for supervised or unsupervised patient use.
Supporters argue
Supporters argue this change is vital for expanding treatment access, especially in underserved areas, by moving methadone prescribing closer to mainstream medical practice and reducing the stigma associated with OTP-only dispensing.
Critics contend
Critics may contend that moving methadone dispensing outside the highly structured OTP environment could increase risks of diversion and misuse, potentially compromising patient safety and public health.
Tradeoffs
This provision balances the urgent need to expand access to life-saving OUD treatment against concerns regarding the potential for increased diversion and the importance of comprehensive, integrated care traditionally provided by OTPs.
Section 2, amending 21 U.S.C. 823(h)(2)(B)
Practitioner Qualification Standards
This section defines who qualifies to prescribe methadone for OUD under the new model. It specifies that practitioners must be licensed to prescribe controlled substances and hold specific subspecialty board certifications in addiction medicine or addiction psychiatry. Alternatively, the Secretary of Health and Human Services can determine other qualifications for practitioners to be eligible.
Section 2, amending 21 U.S.C. 823(h)(2)(C)
Prescribing and Dispensing Requirements
This provision outlines specific operational requirements for prescribing and dispensing methadone under the new model. Prescriptions must be exclusively electronic, comply with federal and state quantity limits, and be for liquid or dispersible tablet formulations. It also clarifies that pharmacy dispensing is in addition to other care patients receive from an OTP.
Section 2, amending 21 U.S.C. 823(h)(2)(F)
State Opt-Out Provision
This provision grants states the authority to opt out of the new methadone prescribing and pharmacy dispensing model. Upon a state's request, the Attorney General must cease registering new practitioners in that state, revoke existing registrations, and deny pending applications for such registrations.
Section 2, amending 21 U.S.C. 823(h)(2)(G) and (H)
Telemedicine and Pharmacy Registration Exemption
This section explicitly allows maintenance or detoxification treatment provided under the new methadone prescribing model to be delivered through telemedicine. Additionally, it clarifies that pharmacies dispensing methadone prescribed by a registered practitioner under this Act are not required to obtain a separate registration for this purpose.
Section 2, amending 21 U.S.C. 823(h)(3)
DEA Annual Reporting Requirements
This provision mandates that the Administrator of the Drug Enforcement Administration (DEA) submit an annual report to Congress, starting 180 days after the Act's enactment. The report must include the number of practitioners registered under the new methadone prescribing model in each state, a list of states that have opted out, the number of registration revocations or suspensions related to methadone prescribing violations, and the number of pharmacies ordering liquid or dispersible tablet methadone formulations.
Requires specific informed consent regarding differences in confidentiality protections when dispensing methadone through a pharmacy versus an opioid treatment program (OTP).
Section 2, amending 21 U.S.C. 823(h)(2)(E)(ii)
Why it matters:This is standard legislative practice to include specific requirements within broader operational mandates, rather than as standalone provisions.
Case for: Supporters argue this explicit consent is vital for patient autonomy, ensuring individuals understand potential privacy implications when choosing a pharmacy-based model over an OTP, which typically has stricter federal confidentiality rules (42 CFR Part 2).
Case against: No specific case against this provision is typically raised, as it aims to protect patient rights and transparency. Some might argue it adds a layer of complexity to the consent process.
Estimated impact: Ensures patients are fully aware of their privacy rights and the differences between treatment settings, potentially influencing their choice of care model.
Clarifies that the dispensing of methadone to an individual through a pharmacy under this new model shall be 'in addition to the other care that the individual continues to have access to through an opioid use disorder treatment program.'
Section 2, amending 21 U.S.C. 823(h)(2)(D)
Why it matters:This is standard legislative practice to include clarifying or limiting conditions within the operational details of a new program.
Case for: Proponents emphasize this ensures patients receive comprehensive care, including counseling and support services typically offered by OTPs, rather than just medication. It prevents the new model from inadvertently fragmenting care.
Case against: Some might argue that requiring continued access to OTPs, even if not mandatory attendance, could still present a logistical barrier for patients who sought pharmacy dispensing precisely to avoid OTP-related challenges.
Estimated impact: Reinforces the importance of holistic OUD treatment, potentially mitigating concerns that expanded pharmacy access would lead to medication-only treatment without necessary behavioral health support.